Kyntra Bio Overview
Valuation check: KYNB's ROE is -2249.41%, below the Healthcare sector average of -75.59%.
Get informed when a big investor buys or sells
+ Follow-2249.41%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Kyntra Bio (KYNB) currently reports a ROE of -2249.41%. That is below the Healthcare sector average of -75.59%. Use the charts on this page to explore Kyntra Bio's ROE history and peer comparisons.
Kyntra Bio's ROE of -2249.41% is lower than the Healthcare sector average of -75.59%. That is roughly 2875.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Kyntra Bio's current -2249.41% should be judged against Healthcare norms (sector average: -75.59%) and against KYNB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -2249.41%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Kyntra Bio, and consider following KYNB for alerts when major investors trade the stock.
Kyntra Bio is classified in the Healthcare sector. On ROE, it currently shows -2249.41% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KYNB with unrelated industries.
